Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca is supported by increasingly compelling early clinical evidence for ERAS-0015, with 40% to 57% uORR in U.S. 2L+ PDAC and about 75% pooled post-ICI/platinum NSCLC, while maintaining a median 100% dose intensity and manageable safety, suggesting meaningful potency without an obvious loss of therapeutic window. The company also has multiple near-term catalysts, including first ERAS-4001 data in 2H26 and potentially registration-enabling ERAS-0015 studies beginning in 2027, which strengthens the case that its RAS/MAPK strategy could evolve into a broader franchise rather than a single-asset story. Financially, the $500M equity raise and $409M in cash and equivalents at 2Q provide a stronger runway to execute the pipeline, reducing near-term funding pressure as development advances.

Erasca is viewed negatively because its investment case depends on a highly uncertain clinical-stage pipeline, where ERAS-0015 and ERAS-4001 still face meaningful R&D, regulatory, and commercial execution risk before any durable revenue can materialize. Its narrow focus on RAS/MAPK-driven cancers also concentrates exposure to development setbacks, intellectual property disputes, management missteps, and the possibility that emerging competitors could weaken the commercial opportunity or compress eventual product sales. With only two clinical-stage programs and one discovery-stage asset, the company remains heavily reliant on successful data generation and strategic execution, making the thesis vulnerable to multiple downside scenarios.